Description
Description
Stenbolone was developed as a mild alternative to the same toxic company Anadrol. And the company succeeded because Stenbolone is neither toxic to the liver nor aromatizing, and it is only mildly androgenic. Also, it has an effect similar to Anadrol in cases of anemia with abnormal blood formation as it increases the number of red blood cells. For this reason, Stenbolone is particularly suitable for competitive athletes as it accelerates regeneration when dieting. Competing bodybuilders in the weeks leading up to a championship often experience a catabolic phase and an overtraining condition. Stenbolone quickly and reliably counteracts this and helps to get in good shape because it does not pull water or increase estrogen levels. For strength and mass buildup, however, Stenbolone is by far not as suitable as Anadrol, although some mistakenly call it an injectable Anadrol. Stenbolone has lower anabolic and androgenic effects than the oral version and it leads to slow but solid muscle gain with moderate strength gain. For this purpose, it is preferred by women and steroid novices, and by older athletes who achieve satisfactory results without fear of significant side effects.Despite this, Stenbolone is, above all, a competition steroid which is confirmed by American Steroid Guru Daniel Duchaine in his book Underground Steroid Handbook 2: It is an excellent steroid to use while dieting
Since the substance is in the form of acetate, it has only a short half-life so that frequent and regular injections are necessary in order to obtain a sufficiently high and constant blood level value. For optimal results Stenbolone is normally taken daily and injected at least every 2 days. The usual weekly dose for athletes is 200-300 mg. For this reason, the 50mg strength is often preferred and the athlete injects the entire one milliliter ampule daily or limits usage to half of it. Women normally do well with 100-150 mg/week and should divide their weekly dose into three equal parts.
Reviews
There are no reviews yet.